InMed Pharmaceuticals (INM) Retained Earnings (2020 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Retained Earnings of -$124.0 million for Q1 2026, down 96546.27% year-over-year from N/an in Q1 2025, and down 2.49% quarter-over-quarter from -$121.0 million in Q4 2025.
InMed Pharmaceuticals (INM) Retained Earnings (2020 - 2026) Analysis & Trends
InMed Pharmaceuticals' Retained Earnings history runs 7 years deep, the most recent figure standing at -$124.0 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 96546.27% year-over-year to -$124.0 million; the TTM figure through Mar 2026 stood at -$124.0 million (down 96546.27% YoY), while the FY2025 annual figure was $128569.0, changed 0.0% from the prior year.
- Retained Earnings for Q1 2026 stood at -$124.0 million, down from -$121.0 million in the prior quarter.
- The five-year high for Retained Earnings was $128569.0 in Q2 2022, with the low at -$124.0 million in Q1 2026.
- The 5-year median for Retained Earnings is $128569.0 (2022), against an average of -$45.4 million.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings jumped 100.17% in 2022, then plunged 96546.27% in 2026.
- InMed Pharmaceuticals' Retained Earnings stood at -$99.1 million in 2022, then soared by 100.13% to $128569.0 in 2023, then slumped by 88223.89% to -$113.3 million in 2024, then retreated by 6.79% to -$121.0 million in 2025, then fell by 2.49% to -$124.0 million in 2026.
- Business Quant data shows INM's Retained Earnings at -$124.0 million in Q1 2026, -$121.0 million in Q4 2025, and -$119.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 3.75 Bn |
| 10 | InMed Pharmaceuticals | 6.36 Mn | 1.11 Mn | - | -124.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -124.00 Mn |
| Dec 31, 2025 | -120.99 Mn |
| Sep 30, 2025 | -119.00 Mn |
| Jun 30, 2025 | 128,569.00 |
| Mar 31, 2025 | 128,569.00 |
| Dec 31, 2024 | -113.30 Mn |
| Sep 30, 2024 | -110.75 Mn |
| Jun 30, 2024 | 128,569.00 |
| Mar 31, 2024 | 128,569.00 |
| Dec 31, 2023 | 128,569.00 |
| Sep 30, 2023 | 128,569.00 |
| Jun 30, 2023 | 128,569.00 |
| Mar 31, 2023 | 128,569.00 |
| Dec 31, 2022 | -99.06 Mn |
| Sep 30, 2022 | 128,569.00 |
| Jun 30, 2022 | 128,569.00 |
| Mar 31, 2022 | -85.58 Mn |
| Dec 31, 2021 | -82.11 Mn |
| Sep 30, 2021 | -77.82 Mn |
| Jun 30, 2021 | 21.51 Mn |